Standing ovation for Gilead as it boasts perfect efficacy in HIV PReP trial
Gilead received a standing ovation after announcing its full, perfect efficacy data from the Phase III PURPOSE 1 trial of…
Gilead received a standing ovation after announcing its full, perfect efficacy data from the Phase III PURPOSE 1 trial of…
The UNAIDS executive director has called upon Gilead Sciences to make its ‘miracle’ drug lenacapavir for human immunodeficiency virus (HIV)…
Researchers will present data from a ‘first-of-its-kind HIV cure’ stem cell transplant at the upcoming AIDS 2024 Conference. Experts will…
On 4 July 2024, the people of the UK took to the polls and made their voice heard, voting for…
Novo Nordisk has said it will take a DKr5.7bn ($816m) hit after its acquired drug ocedurenone flopped in the Phase…
The chief executive of the National Health Service (NHS) England spoke about her desire to ‘bolster management and leadership’ after…
Questions about a change of primary endpoint, treatment cessation and mortality reporting will be asked by a US Food and…
Patient-centricity has been a buzzword in the clinical trial industry for the past few years with all the big pharma…
In October 2023, Katalin Karikó, PhD and Drew Weissman, PhD won the Nobel Prize in Physiology or Medicine for their…
An AI database that utilises real-world data (RWD) could help sponsors decide where to next investigate glucagon-like peptide-1 receptor agonists…